Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies is a research paper published in Cancers (2020). On theSindex it has a DataRank of 0. It has been cited 67 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Wetenschappelijk Fonds Willy Gepts
Grant: N/A
FWCI
4.50
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
Additional file 1 of Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial